Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20060260623 A1
Publication typeApplication
Application numberUS 11/414,041
Publication dateNov 23, 2006
Filing dateApr 28, 2006
Priority dateOct 4, 2002
Also published asCA2500855A1, CA2635955A1, EP1545387A1, US7107992, US20040112390, WO2004032798A1
Publication number11414041, 414041, US 2006/0260623 A1, US 2006/260623 A1, US 20060260623 A1, US 20060260623A1, US 2006260623 A1, US 2006260623A1, US-A1-20060260623, US-A1-2006260623, US2006/0260623A1, US2006/260623A1, US20060260623 A1, US20060260623A1, US2006260623 A1, US2006260623A1
InventorsStephen Brooks, Jed Black
Original AssigneeBrooks Stephen N, Black Jed E
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
System and method for preventing closure of passageways
US 20060260623 A1
Abstract
A system for treating sleep-related breathing disorders. In one embodiment, the system includes a first magnetically susceptible material attached to a left lateral pharyngeal wall and a second magnetically susceptible material attached to a right lateral pharyngeal wall. The second magnetically susceptible material is positioned opposite the first magnetically susceptible material across an upper airway. The system further includes a first magnet disposed outside the body and lateral to the first magnetically susceptible material, and a second magnet disposed outside the body and lateral to the second magnetically susceptible material.
Images(8)
Previous page
Next page
Claims(5)
1. A system for treating sleep-related breathing disorders, comprising: a first magnet attached to a left lateral pharyngeal wall; and a second magnet attached to a right lateral pharyngeal wall, wherein the second magnet is positioned opposite the first magnet across an upper airway, and wherein the first and second magnets are positioned below the velopharynx and above the epiglottis.
2. The system of claim 1, wherein the first and second magnets are implanted inside the lateral pharyngeal walls.
3. The system of claim 1, wherein the first magnet and the second magnet are attached to the left and right lateral pharyngeal walls by one of surgical sutures, a bonding material and coating.
4. The system of claim 1, wherein the first and second magnets are one of permanent and variable magnets.
5. A method for treating sleep-related breathing disorders, comprising: attaching a first magnet to a left lateral pharyngeal wall; and attaching a second magnet to a right lateral pharyngeal wall opposite the first magnet across an upper airway.
Description
    CROSS-REFERENCE
  • [0001]
    This application is a continuation of Ser. No. 10/679,935, filed Oct. 6, 2003, which claims benefit of U.S. Provisional patent application Ser. No. 60/415,995, filed Oct. 4, 2002, both of which are herein incorporated by reference.
  • BACKGROUND OF THE INVENTION
  • [0002]
    1. Field of the Invention
  • [0003]
    Embodiments of the present invention generally relate to prevention of abnormal breathing sounds (e.g., snoring), adverse consequences, illness or death in persons due to partial or complete blockage of the upper airway.
  • [0004]
    2. Description of the Related Art
  • [0005]
    A common and potentially serious disorder in humans involves involuntary closure of the airway during sleep. This disorder is known as “sleep-disordered breathing” or “obstructive sleep apnea” (OSA). In persons with OSA, there is involuntary closure or reduction in caliber of a portion of the airway that connects the atmosphere to the lungs. The upper portion of the airway (the “upper airway”) consists of two passageways, the nasal airway and the oral airway. These two passageways merge to become a single passageway. Portions of the upper airway just behind the tongue are known as the soft palate, the pharynx, the hypopharynx, etc.
  • [0006]
    In persons affected by OSA, closure, reduction in patency or increased airflow resistance of the upper airway occurs during sleep, due to a combination of physiological changes associated with sleep (including relaxation of muscles) and the anatomy of the upper airway (which is generally smaller or more crowded than in normal individuals). In persons prone to sleep apnea, a portion or portions of the muscular walls of the upper airway may become narrow or collapse, leading to reduction in airflow (“hypopnea”), cessation of airflow (“apnea”), increase in airflow turbulence or increased resistance to airflow within the airway. In the instance of collapse, the upper airway is blocked, breathing stops, air movement to the lungs ceases, and the oxygen level in the blood tends to decrease. As a response to this process (or to less severe manifestations, such as hypopneas or increased airway resistance), a brief arousal usually occurs in the brain. As a consequence of the brief arousal, the muscle tone in the walls of the upper airway returns to waking levels, and the airway abnormality is corrected—i.e. airway resistance and patency return to normal levels.
  • [0007]
    Generally, following each event, the patient returns to sleep, until another partial or complete upper airway collapse occurs and the process repeats itself. Depending on the severity in an individual case, the number of events may range from a few per hour of sleep to more than 100 events per hour of sleep. This process disrupts normal sleep. As a consequence, patients typically suffer from the effects of sleep deprivation. Such effects may include daytime drowsiness, tiredness or fatigue, difficulties with mental concentration or memory, mood changes, reductions in performance or increases in mistakes, and increased risk of accidents. Additionally, OSA is known to increase the risk of development of other medical problems.
  • [0008]
    Snoring is a mild form of sleep-disordered breathing in which increased airflow turbulence occurs. The snoring sounds result from tissue vibration within the nasal or oral airway. While snoring has been traditionally regarded as a social or cosmetic problem, recent studies suggest that snoring may be linked to the development of health problems, including high blood pressure.
  • [0009]
    Airway closure during sleep generally occurs at one or both of two levels in the upper airway: the soft palate and the hypopharynx (base of the tongue). At either level, the anterior tissue can collapse against the posterior pharyngeal wall, which makes up the rear wall of the throat. Additionally, the side (lateral) walls of the upper airway can collapse inward partially, or completely against each other. The lateral walls of the airway are susceptible to collapse in many patients with obstructive sleep apnea and other forms of sleep-related breathing disorders. In these cases, prevention of collapse of the airway only in the anterior-posterior dimension is insufficient to maintain normal airway patency. Even after extensive airway surgery for sleep apnea (which primarily addresses the anterior-posterior dimension of the airway), the patient may continue to have problems with breathing during sleep, due to lateral wall collapse or dysfunction.
  • [0010]
    Several types of treatment are available for obstructive sleep apnea and other sleep-related breathing disorders. The most common treatment consists of an air pressure delivery system that applies greater than atmospheric pressure to all walls of the upper airway to reduce the potential for full or partial collapse. Many people have difficulty using this device or prefer not to use it for various reasons. Also, surgical reconstruction of the airway or dental devices may be used. These treatments, however, often fail to treat the problem adequately.
  • [0011]
    Accordingly, a need exists in the art for an improved method and system for treating sleep apnea and other sleep-related breathing disorders.
  • SUMMARY OF THE INVENTION
  • [0012]
    Embodiments of the present invention are generally directed to a system for treating sleep-related breathing disorders. In one embodiment, the system includes a first magnet attached to a left lateral pharyngeal wall, and a second magnet attached to a right lateral pharyngeal wall. The second magnet is positioned opposite the first magnet across an upper airway.
  • [0013]
    In another embodiment, the system includes a first magnetically susceptible material attached to a left lateral pharyngeal wall and a second magnetically susceptible material attached to a right lateral pharyngeal wall. The second magnetically susceptible material is positioned opposite the first magnetically susceptible material across an upper airway. The system further includes a first magnet disposed outside the body and lateral to the first magnetically susceptible material, and a second magnet disposed outside the body and lateral to the second magnetically susceptible material.
  • [0014]
    In yet another embodiment, the system includes a first magnet attached to a left lateral pharyngeal wall and a second magnet attached to a right lateral pharyngeal wall. The second magnet is positioned opposite the first magnet across an upper airway. The system further includes a third magnet disposed inside the upper airway directly across from the first magnet and a fourth magnet disposed inside the upper airway directly across from the second magnet.
  • INCORPORATION BY REFERENCE
  • [0015]
    All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0016]
    The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0017]
    The following detailed description makes reference to the accompanying drawings, which are now briefly described.
  • [0018]
    FIG. 1A, 1B, 3, 4A and 5 illustrate a series of coronal views of an upper airway, each having a system for treating sleep-related breathing disorders in accordance with one embodiment of the invention.
  • [0019]
    FIG. 2 illustrates a sagittal view of the upper airway having a system for treating sleep-related breathing disorders in accordance with one embodiment of the invention.
  • [0020]
    While the invention is described herein by way of example for several embodiments and illustrative drawings, those skilled in the art will recognize that the invention is not limited to the embodiments or drawings described. It should be understood, that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the present invention as defined by the appended claims. The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claims. As used throughout this application, the word “may” is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must). Similarly, the words “include”, “including”, and “includes” mean including, but not limited to.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0021]
    While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
  • DETAILED DESCRIPTION
  • [0022]
    FIG. 1A illustrates a coronal view of an upper airway 100 having a system for treating sleep apnea (and other sleep-related breathing disorders, e.g., snoring) in accordance with one embodiment of the invention. The upper airway 100 is generally defined by the anterior pharyngeal wall 110, two lateral pharyngeal walls 120, 130 and the posterior pharyngeal wall 140. The lateral pharyngeal walls 120, 130 generally include lateral pharyngeal tissue extending superiorly to the velopharynx and inferiorly to the epiglottis. The posterior pharyngeal wall 140 generally includes posterior pharyngeal tissue extending superiorly to the velopharynx and inferiorly to the epiglottis. The anterior pharyngeal wall 110 generally includes a base portion of the tongue 150, the soft palate 210 and the uvula 220 (shown in FIG. 2). Magnetically susceptible material 115 is attached to the anterior pharyngeal wall 110, magnetically susceptible material 125 is attached to the lateral pharyngeal wall 120, and magnetically susceptible material 135 is attached to the lateral pharyngeal wall 130. In one embodiment, magnetically susceptible materials 115, 125, 135 are attached to the respective pharyngeal walls by surgical sutures or bonding material, such as surgical glue. Other means for attaching the magnetically susceptible materials to the pharyngeal walls are also contemplated by embodiments of the invention described herein. In another embodiment, the magnetically susceptible materials 115, 125, 135 may be implanted inside, or embedded beneath the surface of, the respective pharyngeal walls, as shown in FIG. 1B. In yet another embodiment, the magnetically susceptible materials 115, 125, 135 may be coated on the surfaces of the respective pharyngeal walls.
  • [0023]
    The magnetically susceptible materials 115, 125, 135 may be materials, which are not magnets, but are susceptible to magnetic fields, such as ferromagnetic materials. As such, magnetically susceptible materials 115, 125, 135 would not interact with each other in the absence of a magnetic field, such as, during daytime, as opposed to permanent magnets that would potentially interact with each other at all times, which may be inappropriate or even deleterious (e.g., during speaking or swallowing) to a person's health. Magnetically susceptible materials 115, 125, 135 may be in the form of plates, discs, spheres, bars, multiple small pieces, mesh and the like. In an alternate embodiment, the magnetically susceptible materials 115, 125, 135 may be replaced with magnets, such as permanent magnets with magnetic fields of fixed strength or variable magnets (e.g., electromagnets) with magnetic fields of variable strength (including zero if not activated).
  • [0024]
    Magnet 160 is positioned outside the body and lateral to magnetically susceptible material 125, while magnet 170 is positioned outside the body and lateral to magnetically susceptible material 135, and magnet 180 is positioned outside the body and anterior to magnetically susceptible material 115. Magnets 160, 170, 180 may be attached or placed adjacent to the outer skin 151 of a patient with means, such as a neckband or a chin strap. In one embodiment, magnets 160, 170, 180 may be implanted beneath the outer skin surface, such as, beneath the front skin 211 of the cheek 266 for magnet 160, as shown in FIG. 2.
  • [0025]
    Magnet 160 is configured to attract magnetically susceptible material 125 toward magnet 160 so that movement of the lateral pharyngeal wall 120 toward closure of the upper airway 100 may be opposed. Magnet 170 is configured to attract magnetically susceptible material 135 toward magnet 170 so that movement of the lateral pharyngeal wall 130 toward closure of the upper airway 100 may be opposed. Magnet 180 is configured to attract magnetically susceptible material 115 toward magnet 180 so that movement of the anterior pharyngeal wall 110 toward closure of the upper airway 100 may be opposed. In this manner, the cross sectional dimensions (e.g., the length or width) of the upper airway 100 may be increased or prevented from decreasing, thereby allowing patency of the upper airway 100 to be maintained.
  • [0026]
    Force fields between magnet 160 and magnetically susceptible material 125 and between magnet 170 and magnetically susceptible material 135 act to keep the soft tissue of the lateral pharyngeal walls 120, 130 from collapsing. Force fields between magnet 180 and magnetically susceptible material 115 act to keep the soft tissue of the anterior pharyngeal wall 110 from collapsing toward the posterior pharyngeal wall 140.
  • [0027]
    FIG. 3 illustrates a coronal view of an upper airway 300 having a system 350 for treating sleep apnea (and other sleep-related breathing disorders, e.g., snoring) in accordance with another embodiment of the invention. The system 350 includes magnet 315 attached to an anterior pharyngeal wall 310, magnet 325 attached to lateral pharyngeal wall 320, magnet 335 attached to lateral pharyngeal wall 330, and magnet 345 attached to posterior pharyngeal wall 340. In one embodiment, magnets 315, 325, 335, 345 are attached to the respective pharyngeal walls by surgical sutures or bonding material, such as surgical glue. Other means for attaching the magnets to the pharyngeal walls are also contemplated by embodiments of the invention described herein. In another embodiment, magnets 315,325, 335, 345 may be implanted inside (e.g., embedded beneath the surface of) the respective pharyngeal walls. In yet another embodiment, magnets 315, 325, 335, 345 may be coated on surfaces of the respective pharyngeal walls.
  • [0028]
    Magnets 315, 325, 335, 345 may be permanent magnets with magnetic fields of fixed strength or variable magnets, such as electromagnets, with magnetic fields of variable strength (including zero if not activated).
  • [0029]
    Magnets 315, 325,335,345 are oriented such that the same magnetic poles of the magnets 315,325, 335,345 face each other, e.g., north poles facing other north poles. In operation, magnets 315, 325, 335, 345 are configured to repel each other, thereby opposing closure of the upper airway 300 without the use of external magnets.
  • [0030]
    FIG. 4A illustrates a coronal view of an upper airway 400 having a system 450 for treating sleep apnea (and other sleep-related breathing disorders, e.g., snoring) in accordance with yet another embodiment of the invention. The system 450 includes magnet 425 attached to lateral pharyngeal wall 420 and magnet 435 attached to lateral pharyngeal wall 430. In one embodiment shown in FIG. 4B, magnets 425, 435 are attached to the respective lateral pharyngeal walls by surgical sutures or bonding material, such as surgical glue 436. Other means for attaching the magnets to the lateral pharyngeal walls are also contemplated by embodiments of the invention described herein. In another embodiment, magnets 425, 435 may be implanted inside (e.g., embedded beneath the surface of) the respective lateral pharyngeal walls. In yet another embodiment, magnets 425, 435 may be coated on surfaces of the respective lateral pharyngeal walls.
  • [0031]
    Magnets 425, 435 may be permanent magnets with magnetic fields of fixed strength or variable magnets, such as electromagnets, with magnetic fields of variable strength (including zero if not activated). Magnets 425, 435 are oriented such that the same magnetic poles of the magnets 425, 435 face each other, e.g., north pole facing other north pole. In operation, magnets 425, 435 are configured to repel each other, thereby opposing closure of the upper airway 400 without the use of external magnets.
  • [0032]
    FIG. 5 illustrates a system 550 for treating sleep apnea (and other sleep-related breathing disorders, e.g., snoring) disposed inside an upper airway 500 in accordance with still another embodiment of the invention. The system 550 includes magnet 525 attached to lateral pharyngeal wall 520 and magnet 535 attached to lateral pharyngeal wall 530. In one embodiment, magnets 525, 535 may be attached to the lateral pharyngeal walls 530, 535 by surgical sutures or bonding material, such as surgical glue. Other means for attaching the magnets to the pharyngeal walls are also contemplated by embodiments of the invention described herein. In another embodiment, magnets 525, 535 may be implanted inside the lateral pharyngeal walls 530, 535. In yet another embodiment, magnets 525, 535 may be coated on surfaces of the lateral pharyngeal walls 530, 535. Magnets 525, 535 may be permanent magnets with magnetic fields of fixed strength or variable magnets, such as electromagnets, with magnetic fields of variable strength (including zero if not activated).
  • [0033]
    The system 550 further includes magnets 560 and 570 disposed inside the upper airway 500. Magnet 560 is disposed across from magnet 525, while magnet 570 is disposed across from magnet 535. The magnetic poles of magnets 560, 570 are oriented such that magnets 560, 570 repel magnets 525, 535, respectively, thereby opposing closure of the upper airway 500 without the use of external magnets. Magnets 560, 570 may be attached to or held in place by a removable apparatus 580, such as a mouthpiece.
  • [0034]
    Each magnet or magnetically susceptible material described herein may comprise more than one magnet or magnetially susceptible material. Although embodiments of the invention have been described with reference to two or four magnetially susceptible materials or magnets, embodiments of the invention also contemplate other combinations or numbers of magnets and magnetically susceptible materials. Although embodiments of the invention have been described with reference to treating sleep-related breathing disorders, such as sleep apnea or snoring, embodiments of the invention also contemplate other applications where passageway or airway patency is required. For example, the magnets or magnetically susceptible materials may be inserted or attached through a body aperture, such as the vagina, the rectum, the urinary passage and the like.
  • [0035]
    While the foregoing is directed to embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US5176618 *Aug 27, 1990Jan 5, 1993George FreedmanSystem for preventing closure of passageways
US6955172 *Sep 6, 2002Oct 18, 2005Apneon, Inc.Systems and methods for moving and/or restraining the tongue in the oral cavity
US20030149488 *Sep 6, 2002Aug 7, 2003Metzger Anja K.Stiffening pharyngeal wall treatment
US20040045556 *Sep 6, 2002Mar 11, 2004Swan MedicalSystems and methods for moving and/or restraining tissue in the upper respiratory system
US20070137655 *Nov 3, 2006Jun 21, 2007Apneon, Inc.Devices, systems and methods using magnetic force systems affecting the tongue or hyoid muscles in the upper airway
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8167787Jan 3, 2008May 1, 2012Revent Medical, Inc.Partially erodable systems for treatment of obstructive sleep apnea
US8327854Oct 7, 2011Dec 11, 2012Revent Medical, Inc.Partially erodable systems for treatment of obstructive sleep apnea
US8523760Apr 10, 2012Sep 3, 2013Revent Medical, Inc.Partially erodable systems for treatment of obstructive sleep apnea
US8707960May 11, 2009Apr 29, 2014Revent Medical, Inc.Partially erodable systems for treatment of obstructive sleep apnea
US8733363Mar 21, 2011May 27, 2014Revent Medical, Inc.Systems and methods for treatment of sleep apnea
US8747296Jul 30, 2013Jun 10, 2014Revent Medical, Inc.Partially erodable systems for treatment of obstructive sleep apnea
US8776799Mar 21, 2011Jul 15, 2014Revent Medical, Inc.Systems and methods for treatment of sleep apnea
US8991398Dec 11, 2012Mar 31, 2015Revent Medical, Inc.Partially erodable systems for treatment of obstructive sleep apnea
US9381109May 28, 2014Jul 5, 2016Revent Medical, Inc.Systems and methods for treatment of sleep apnea
US9439801Jun 29, 2012Sep 13, 2016Revent Medical, Inc.Systems and methods for treatment of sleep apnea
US9510922May 23, 2011Dec 6, 2016Revent Medical, Inc.Systems and methods for treatment of sleep apnea
US20090177027 *Jan 3, 2008Jul 9, 2009Gillis Edward MPartially erodable systems for treatment of obstructive sleep apnea
US20110144421 *May 11, 2009Jun 16, 2011Gillis Edward MPartially erodable systems for treatment of obstructive sleep apnea
Classifications
U.S. Classification128/863
International ClassificationA61F2/00, A61B19/00, A61F5/56
Cooperative ClassificationY10S602/902, A61F2210/009, A61N2/004, A61F5/566, A61N2/06
European ClassificationA61F5/56B, A61N2/00T